Sign In
Buy AMPH
$19.94
-0.440 (-2.16%)
At Close: Jul 31, 2026
Amphastar Pharmaceuticals: Cheap With Caveats
12:48pm, Friday, 03'rd Jan 2025
Amphastar Pharmaceuticals' stock has declined over 25% since early November, despite solid earnings and sales growth, presenting a potential buying opportunity. Q3 results were impacted somewhat by th
New Strong Sell Stocks for January 2nd
06:56am, Thursday, 02'nd Jan 2025
AGCO, AMPH and ASC have been added to the Zacks Rank #24 (Strong Sell) List on January 2, 2024.
New Strong Sell Stocks for December 31st
06:51am, Tuesday, 31'st Dec 2024
AGL, AMPH and CR have been added to the Zacks Rank #24 (Strong Sell) List on December 31, 2024.
Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference
04:05pm, Tuesday, 26'th Nov 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participa
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
04:05pm, Wednesday, 13'th Nov 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, wil
Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Transcript
09:12pm, Wednesday, 06'th Nov 2024
Amphastar Pharmaceuticals Inc. (AMPH) Q3 2024 Earnings Call Transcript
Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings
07:00pm, Wednesday, 06'th Nov 2024
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall S
Amphastar Pharmaceuticals (AMPH) Lags Q3 Earnings and Revenue Estimates
06:36pm, Wednesday, 06'th Nov 2024
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.15 per share a year ago.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024
04:05pm, Wednesday, 06'th Nov 2024
Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" o
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Wednesday, 30'th Oct 2024
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024
06:00am, Tuesday, 29'th Oct 2024
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2024 ended September 30, 2
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
10:45am, Friday, 25'th Oct 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Will Amphastar (AMPH) Beat Estimates Again in Its Next Earnings Report?
01:16pm, Friday, 18'th Oct 2024
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amphastar Pharmaceuticals Inc (AMPH) Trading Down 3.54% on Oct 2
12:08pm, Wednesday, 02'nd Oct 2024
Shares of Amphastar Pharmaceuticals Inc (AMPH, Financial) fell 3.54% in mid-day trading on Oct 2. The stock reached an intraday low of $46.58, before recovering slightly to $46.64, down from its previ
Amphastar Pharmaceuticals Offers Interesting Growth And Income Prospects
07:20am, Friday, 13'th Sep 2024
Amphastar Pharmaceuticals shows promising growth potential with its diverse product offerings, including the nasally administered glucagon treatment BAQSIMI and the over-the-counter inhalant Primatene
